Anti-CD3/anti-STEAP1 trispecific T-cell engager (Xilio Therapeutics/Abbvie)

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameAnti-CD3/anti-STEAP1 trispecific T-cell engager (Xilio Therapeutics/Abbvie)

Drug Alias NameN/A

ClassificationBiologics > T cell engagersBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody

Mechanisms of ActionCD3 T-cell engagersAnti-STEAP1

TargetsT cell surface glycoprotein CD3Six-transmembrane epithelial antigen of the prostate 1

Therapy Area/IndicationsProstatic NeoplasmsLung NeoplasmsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesXilio Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesXilio Therapeutics Inc Abbvie Inc

Inactive CompaniesN/A

Active IndicationsProstatic NeoplasmsLung NeoplasmsColorectal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A